Company news

Scynexis, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

October 23, 2023

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece

October 15, 2023

SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance

September 26, 2023

SCYNEXIS to Participate in September Investor Conferences

August 27, 2023

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 13, 2023

SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China

July 19, 2023

SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK

June 20, 2023

SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference

June 14, 2023

SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)

May 11, 2023

SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 10, 2023

SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark

April 12, 2023

SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

March 30, 2023

GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

March 29, 2023

SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

November 30, 2022

SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi

November 29, 2022

SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats

November 16, 2022

SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 8, 2022

SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi

November 6, 2022

Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Women’s Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection

November 2, 2022

SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9

October 31, 2022

Biopharma Veteran Ivor Macleod Joins SCYNEXIS as Chief Financial Officer

October 24, 2022

SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

October 23, 2022

SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal

October 19, 2022

SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022

October 10, 2022

SCYNEXIS to Participate in Upcoming September Investor Conferences

September 8, 2022

SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting

September 7, 2022

SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022

August 31, 2022

SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 14, 2022

SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15

August 8, 2022

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

August 3, 2022

SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME® (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections

July 31, 2022

SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease Update

July 18, 2022

SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update

July 13, 2022

SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

June 22, 2022

SCYNEXIS Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

June 7, 2022

SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2022

SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference

May 19, 2022

SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 11, 2022

SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

May 9, 2022

SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12

May 4, 2022

SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

May 3, 2022

SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases

April 26, 2022

SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

April 25, 2022

SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

April 21, 2022

SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

April 21, 2022

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

April 20, 2022

SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal

April 19, 2022

SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives

April 18, 2022

SCYNEXIS to Participate in Upcoming April Women’s Health Medical Conferences

April 3, 2022

SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 28, 2022

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 13 decks. Every deck is listed under its year.